Advertisement

---

SPROUT PHARMACEUTICALS

Sprout Pharmaceuticals Confirms Resubmission To FDA Of Flibanserin For Treatment Of Pre-Menopausal Hypoactive Sexual Desire Disorder

[2013-06-26] - Phase 3 clinical trial, including >1,000 patients, showed positive results
Agency action expected before end of 2013


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers